%0 Journal Article
%T Two Hundred Living Donor Kidney Transplantations Under Alemtuzumab Induction and Tacrolimus Monotherapy: 3-Year Follow-Up
%A Henkie P.Tan
%A Joseph Donaldson
%A Antik Basu
%A Mark Unruh
%A Parmjeet Randhawa
%A Vivek Sharma
%A Claire Morgan
%A Jerry McCauley
%A Cary Wu
%A Nirav Shah
%A Adriana Zeevi and Ron Shapiro
%J American Journal of Transplantation
%P 355-366
%@ 1600-6143
%D 2009
%R 10.1111/j.1600-6143.2008.02492.x
%X Alemtuzumab has been used in off-label studies of solid organ transplantation. We extend our report of the first 200 consecutive living donor solitary kid-ney transplantations under alemtuzumab pretreat-ment with tacrolimus monotherapy and subsequent spaced weaning to 3 years of follow-up. We focused especially on the causes of recipient death and graft loss, and the characteristics of rejection. The actuarial 1-, 2- and 3-year patient and graft survivals were 99.0% and 98.0%, 96.4% and 90.8% and 93.3% and 86.3%, re-spectively. The cumulative incidence of acute cellular rejection (ACR) at the following months was 2% ¡Ü6, 9.0% ¡Ü12, 16.5% ¡Ü18, 19.5% ¡Ü24, 23.5% ¡Ü30, 24.0% ¡Ü36 and 25% ¡Ü42. The mean serum creatinine (mg/dL) and glomerular filtration rate (mL/min/1.73 m2) at 1 and 3 years were 1.4 ¡À 0.6 and 58.7 ¡À 21.6 and 1.5 ¡À 0.7 and 54.9 ¡À 20.9, respectively. Fifty (25%) recipi-ents had a total of 89 episodes of ACR. About 88.7% of ACR episodes were Banff 1, and of those, 82% were steroid-sensitive. Nine (4.5%) recipients had antibody-mediated rejection (AMR). About 76.5% were weaned but only 46% are currently on spaced dose (qod or less) tacrolimus monotherapy, and 94.4% remained steroid-free from the time of transplantation. Infectious com-plications were uncommon. This experience suggests the 3-year efficacy of this approach.
%K Acute cellular rejection
%K African American
%K antibody-mediated rejection
%K Campath-1H
%K chronic al-lograft nephropathy
%K focal segmental glomeruloscle-rosis
%K HIV
%K induction
%K interstitial fibrosis
%K laparoscopic live donor nephrectomy
%K pediatric
%K steroid avoidance
%K steroid free
%K tubular atrophy
%U http://onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2008.02492.x/abstract